108 related articles for article (PubMed ID: 20573806)
1. Tranilast attenuates the up-regulation of thioredoxin-interacting protein and oxidative stress in an experimental model of diabetic nephropathy.
Tan SM; Zhang Y; Cox AJ; Kelly DJ; Qi W
Nephrol Dial Transplant; 2011 Jan; 26(1):100-10. PubMed ID: 20573806
[TBL] [Abstract][Full Text] [Related]
2. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy.
Hamada Y; Fukagawa M
Kobe J Med Sci; 2007; 53(1-2):53-61. PubMed ID: 17582205
[TBL] [Abstract][Full Text] [Related]
3. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
[TBL] [Abstract][Full Text] [Related]
4. Thioredoxin-interacting protein: a potential therapeutic target for treatment of progressive fibrosis in diabetic nephropathy.
Tan CY; Weier Q; Zhang Y; Cox AJ; Kelly DJ; Langham RG
Nephron; 2015; 129(2):109-27. PubMed ID: 25662516
[TBL] [Abstract][Full Text] [Related]
5. Thioredoxin-Interacting Protein Deficiency Protects against Diabetic Nephropathy.
Shah A; Xia L; Masson EA; Gui C; Momen A; Shikatani EA; Husain M; Quaggin S; John R; Fantus IG
J Am Soc Nephrol; 2015 Dec; 26(12):2963-77. PubMed ID: 25855771
[TBL] [Abstract][Full Text] [Related]
6. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
[TBL] [Abstract][Full Text] [Related]
7. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
Elmarakby AA; Sullivan JC
Cardiovasc Ther; 2012 Feb; 30(1):49-59. PubMed ID: 20718759
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates.
Zammit SC; Cox AJ; Gow RM; Zhang Y; Gilbert RE; Krum H; Kelly DJ; Williams SJ
Bioorg Med Chem Lett; 2009 Dec; 19(24):7003-6. PubMed ID: 19879136
[TBL] [Abstract][Full Text] [Related]
9. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: involvement of anti-inflammation and antioxidative stress.
Zhang M; Hagiwara S; Matsumoto M; Gu L; Tanimoto M; Nakamura S; Kaneko S; Gohda T; Qian J; Horikoshi S; Tomino Y
Metabolism; 2006 Dec; 55(12):1590-8. PubMed ID: 17142129
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of oxidative stress and inflammation by gravinol in high glucose-exposed renal tubular epithelial cells.
Kim YJ; Kim YA; Yokozawa T
Toxicology; 2010 Apr; 270(2-3):106-11. PubMed ID: 20149835
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant SOD mimetic prevents NADPH oxidase-induced oxidative stress and renal damage in the early stage of experimental diabetes and hypertension.
Peixoto EB; Pessoa BS; Biswas SK; Lopes de Faria JB
Am J Nephrol; 2009; 29(4):309-18. PubMed ID: 18849601
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
[TBL] [Abstract][Full Text] [Related]
13. Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes.
Jones SE; Gilbert RE; Kelly DJ
J Diabetes Complications; 2004; 18(5):309-15. PubMed ID: 15337505
[TBL] [Abstract][Full Text] [Related]
14. Tranilast: a novel weapon against insulin resistance.
Namazi MR; Soma J
Med Hypotheses; 2005; 64(6):1135-7. PubMed ID: 15823702
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomic profiling identifies new renal targets of copper(II)-selective chelation in the reversal of diabetic nephropathy in rats.
Gong D; Chen X; Middleditch M; Huang L; Vazhoor Amarsingh G; Reddy S; Lu J; Zhang S; Ruggiero K; Phillips AR; Cooper GJ
Proteomics; 2009 Sep; 9(18):4309-20. PubMed ID: 19634143
[TBL] [Abstract][Full Text] [Related]
16. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats.
Anjaneyulu M; Chopra K
Clin Exp Pharmacol Physiol; 2004 Apr; 31(4):244-8. PubMed ID: 15053821
[TBL] [Abstract][Full Text] [Related]
17. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
Usui HK; Shikata K; Sasaki M; Okada S; Matsuda M; Shikata Y; Ogawa D; Kido Y; Nagase R; Yozai K; Ohga S; Tone A; Wada J; Takeya M; Horiuchi S; Kodama T; Makino H
Diabetes; 2007 Feb; 56(2):363-72. PubMed ID: 17259380
[TBL] [Abstract][Full Text] [Related]
18. Thioredoxin interacting protein is increased in sensory neurons in experimental diabetes.
Price SA; Gardiner NJ; Duran-Jimenez B; Zeef LA; Obrosova IG; Tomlinson DR
Brain Res; 2006 Oct; 1116(1):206-14. PubMed ID: 16938273
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of a poly-phytocompound on early stage nephropathy secondary to experimentally-induced diabetes.
Marotta F; Harada M; Dallah ED; Yadav H; Solimene U; Di Lembo S; Minelli E; Jain S; Chui DH
J Biol Regul Homeost Agents; 2010; 24(1):41-9. PubMed ID: 20385070
[TBL] [Abstract][Full Text] [Related]
20. The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.
Arora MK; Reddy K; Balakumar P
Eur J Pharmacol; 2010 Jun; 636(1-3):137-44. PubMed ID: 20347778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
